SHAREHOLDER ALERT: Beta Bionics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses

Beta Bionics, Inc. faces a securities fraud lawsuit for allegedly misleading investors about the safety of its iLet Bionic Pancreas device. The company downplayed FDA concerns about over 18,000 unreported complaints, characterizing them as 'benign' while the FDA warning letter later contradicted these claims. The stock fell from $31.99 to under $13 per share between July 2025 and February 2026. Eligible investors who purchased shares during this period may recover losses.